Kalaris Therapeutics KLRS Income Statement (2019-2026)

NASDAQ KLRS
$2.90 +0.06 (+1.93%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Kalaris Therapeutics Quarterly Income Statement

Periods 29 quarters
Latest Jun 2026

Kalaris Therapeutics reported net income of -$12.39M for the quarter ended Jun 2026. This income statement covers 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
63.18M63.57M64.26M64.79M92.64M76.65M93.43M94.63M113.97M114.15M114.88M115.31M115.44M5.01M4.05M18.70M18.70M15.27M22.99M23.80M
Operating items
Research & DevelopmentR&D
33.06M41.60M29.07M31.38M30.00M28.42M30.72M34.82M34.16M33.37M1.96M3.21M36.02M3.85M6.03M8.44M9.13M7.16M7.57M9.02M
Selling, General & AdministrativeSG&A
12.44M14.19M14.13M13.24M12.95M12.01M12.51M12.48M12.80M10.46M0.60M0.98M1.83M3.28M4.32M3.82M3.62M3.64M4.26M3.37M
Restructuring CostsRestructuring
9.46M0.51M0.08M0.13M
Other Operating ExpensesOther Opex
18.57M0.39M0.42M1.25M2.69M3.65M2.72M2.48M2.10M2.70M2.15M
Operating ExpensesOpex
45.50M55.80M43.19M44.62M42.95M40.43M43.23M47.30M46.96M62.41M2.56M4.19M37.85M7.13M10.35M12.26M12.74M10.80M11.83M12.39M
Operating IncomeOp. Inc
-45.50M-55.80M-43.19M-44.62M-42.95M-40.43M-43.23M-47.30M-46.96M-62.41M-2.56M-4.19M-37.85M-7.13M-10.35M-12.26M-12.74M-10.80M-11.83M-12.39M
EBIT
-45.50M-55.80M-43.19M-44.62M-42.95M-40.43M-43.23M-47.30M-46.96M-62.41M-2.56M-4.19M-37.85M-7.13M-10.35M-12.26M-12.74M-10.80M-11.83M-12.39M
Non-operating items
Non Operating Interest Expenses
0.08M0.50M0.81M1.31M1.44M
Interest & Investment IncomeInt & Inv Inc
0.25M0.08M0.15M0.16M0.67M0.90M1.32M1.52M1.52M1.37M1.25M1.36M1.49M1.39M
Other Non Operating IncomeOther Non Op Inc.
-0.26M-1.22M-0.82M-0.03M0.21M0.98M0.72M0.52M1.17M1.21M0.03M0.31M0.55M1.22M1.23M0.91M0.85M0.80M0.98M0.87M
Non Operating IncomeNon Op. Inc.
-0.84M-1.46M-0.23M-14.89M0.16M0.91M0.85M0.80M0.98M0.87M
Net income details
EBT
-45.51M-56.93M-43.86M-44.49M-42.07M-38.55M-41.91M-45.27M-44.27M-59.82M-1.40M-3.33M-37.17M-7.06M-11.80M-12.26M-12.74M-10.80M-11.83M-12.39M
Tax ProvisionsTaxes
0.20M-0.47M-0.13M
Profit After TaxPAT
-45.51M-56.93M-43.86M-44.69M-42.07M-38.09M-41.91M-45.27M-44.27M-59.70M-1.40M-3.33M-37.17M-7.06M-11.80M-12.26M-12.74M-10.80M-11.83M-12.39M
Income from Continuing OperationsIncome (Continuing)
-45.51M-56.93M-43.86M-44.69M-42.07M-38.09M-41.91M-45.27M-44.27M-59.70M-1.40M-3.33M-37.17M-7.06M-11.80M-12.26M-12.74M-10.80M-11.83M-12.39M
Consolidated Net IncomeConsol Net Inc.
-45.51M-56.93M-43.86M-44.69M-42.07M-38.09M-41.91M-45.27M-44.27M-59.70M-1.40M-3.33M-37.17M-7.06M-11.80M-12.26M-12.74M-10.80M-11.83M-12.39M
Income towards Parent CompanyParent Net Inc
-45.51M-57.98M-43.86M-44.64M-42.10M-38.11M-41.18M-45.27M-44.27M-59.70M-3.41M-5.65M-38.08M-22.06M-10.20M-11.35M-11.89M-10.00M-10.86M-11.52M
Net Income towards Common StockholdersNet Income
-45.51M-57.94M-43.86M-44.64M-42.07M-38.14M-41.18M-45.27M-44.27M-59.70M-30.30M-6.08M-4.13M-18.27M-10.20M-11.35M-11.89M-10.00M-10.86M-11.52M
Additional items
EPS (Basic)
-0.72-0.92-0.69-0.69-0.50-0.50-0.44-0.48-0.39-0.57-0.26-0.05-0.04-3.65-2.52-0.61-0.64-0.65-0.46-0.48
EPS (Diluted)
-0.72-0.92-0.69-0.69-0.50-0.50-0.44-0.48-0.39-0.57-0.26-0.05-0.04-3.65-2.52-0.61-0.64-0.65-0.46-0.48
Shares Outstanding
62.96M62.78M63.99M64.47M84.95M76.65M93.30M94.63M113.89M104.06M114.69M115.13M115.40M5.01M4.05M18.70M18.70M15.27M23.72M23.80M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
62.96M62.78M63.99M64.47M84.95M76.65M93.30M94.63M113.89M104.06M114.69M115.13M115.40M5.01M4.05M18.70M18.70M15.27M23.72M23.80M
EBITDA
-45.46M-55.70M-42.73M-44.54M-42.87M-40.35M-43.15M-47.22M-46.88M-62.27M-10.79M-11.82M-12.38M
Interest ExpensesInt Expense
0.08M0.50M0.81M1.31M1.44M

Kalaris Therapeutics Income Statement API

Pull Kalaris Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=KLRS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY